LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that the Company’s clinical development program with its lead “molecular chaperone” product candidate, arimoclomol, has been chosen as one of the top 10 most interesting neuroscience products available for partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. The committee, led by Marc Wortman, Ph.D., contributing writer to Windhover’s publications In Vivo and Startup, and Harry Tracy, Ph.D., President of NeuroInvestment, an independent resource for investing in neuroscience/pharmaceutical companies, called the selection of arimoclomol a “singular honor” that will draw greater attention from potential investors and partners.
